Business
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new
About this update from Replimune Group, Inc.
[{"type":"text","content":"RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with anti-PD1 failed NMSC Initial data shows clinical activity with RP1 monotherapy in solid organ transplant recipients with cutaneous squamous cell carcinoma (CSCC) Broad Phase 2 development planned for RP2/RP3 in hard-to-treat tumor types Virtual investor event to be held today at 8:00 am ET WOBURN, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced updated data from completed cohorts of the Phase 2 part of the IGNYTE clinical trial in non-melanoma skin cancer (NMSC) and melanoma. Additionally, the Company announced new data from the ongoing clinical trial in anti-PD1 failed NMSC and from the ARTACUS clinical trial, a Phase 1b/2 trial of RP1 (vusolimogene oderparepvec) as monotherapy in solid organ transplant recipients with skin cancer. The Company also provided a detailed overview of its RP2/3 Phase 2 development plans. A virtual investor event will be held today at 8:00 a.m. ET to discuss the updated data. “Today we are pleased to provide a comprehensive clinical update across our pipeline that continues to demonstrate the potential of our oncolytic immunotherapy platform to address a broad range of cancers,” said Philip Astley-Sparke CEO of Replimune. “Updated data from our IGNYTE cohorts in anti-PD1 naïve cutaneous squamous cell carcinoma (CSCC) and anti-PD1 failed melanoma continue to support our two registration-directed studies in these settings. New data presented today also supports our ambition to establish a broad franchise with RP1 in skin cancer, with activity demonstrated in a variety of anti-PD-1/L1 failed non-melanoma skin cancers as well initial data demonstrating utility of RP1 as a monotherapy in solid organ transplant recipient patients where anti-PD1 is contra-indicated. We have seen strong initial data with RP2 monotherapy and in combination with Opdivo® which supports the advancement of RP2/3 into new and difficult to treat tumor types. As a result, we are announcing a broad RP2/3 Phase 2 development plan including new clinical trials in advanc...